LUND, Sweden, June 30, 2022 /PRNewswire/ -- Immunovia today
announced the PanDIA-1 study for the early detection of pancreatic
cancer in newly onset type 2 diabetics is moving into the next
phase. Samples with the associated clinical data have been
transferred to Immunovia from Lund University Diabetes Center
(LUDC). During the second half of 2022 the samples will be analyzed
as the next phase of the development plan for this large risk
"We are entering into a decisive phase of the PanDIA study,
aiming to give another substantial risk group for pancreatic cancer
the ability to get access to early detection. The prevalence of
diabetes is dramatically increasing worldwide, and newly diagnosed
diabetics have an up to 8 times higher risk of being diagnosed with
pancreatic cancer. It is imperative that we change the paradigm,
offer those individuals an option to get tested and allow them to
benefit from treatment options available if diagnosed early", said
Philipp Mathieu, CEO and President
of Immunovia AB.
Immunovia started PanDIA-1 in January
2018 and it is one of the largest, comprehensive prospective
sample collections for early detection of pancreatic cancer in new
onset type 2 diabetics. 6,000 samples have been collected from the
same number of new onset diabetes patients, of which approximately
4,800 are above the age of 50 years. The samples were collected
from new onset diabetic patients starting at the time of diabetes
diagnosis over a 3-year period thereafter, which is the time span
during which patients with new-onset diabetes type 2 have a
dramatically higher risk of developing pancreatic cancer.
The Center for Disease Control and Prevention estimates more
than 37 million Americans have diabetes and approximately 90-95% of
them have type 2 diabetes.
For more information, please contact:
CEO and President
Senior Director Investor Relations and Corporate Communications
+46 736 36 35 74
The information was submitted for publication on June 30, 2022, at 08:30 am
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download: